secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002846
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M
--------------------------------------------------------------------------------

- Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.
- Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.
- Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.
- Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.
- Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/0001104659-25-002846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/tm253044d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer